查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1423666

心臟生物标记的全球市场预测（~2030 年）：按产品类型、测试地点、应用、最终用户和区域进行分析

Cardiac Biomarkers Market Forecasts to 2030 - Global Analysis By Product Type (B-Type Natriuretic Peptide, Creatine Kinase-Muscle/Brain and Other Product Types), By Location of Testing, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

2023年，全球心臟生物标记市场规模为187亿美元，预计预测期内复合年增长率为16.6%，到2030年将达到548亿美元。心臟生物标记是由于心臟受伤、损伤或压力而释放到血液中的特定分子或蛋白质。

肌钙蛋白、肌酸激酶 MB (CK-MB) 和 B 型利钠胜肽(BNP) 等生物标记在诊断上用于指示心臟相关疾病。这些检测到的数值和浓度有助于诊断心臟病、心臟衰竭和其他心臟疾病，确定治疗策略并评估心臟健康状况。

根据世界卫生组织 (WHO) 的数据，18 岁以上的成年人中有 7700 万人患有第 2 型糖尿病，其中 2500 万人患有糖尿病前期。这增加了心血管疾病的风险，并给医疗保健系统带来了进一步的压力。

心血管疾病增加

心肌梗塞、心臟衰竭和心肌缺血等心臟相关疾病的全球负担日益增加，增加了对可靠诊断工具的需求。心臟生物标记是心血管疾病早期发现、诊断和预后的重要指标。它准确评估心臟健康、预测风险和指导治疗策略的能力是高效、及时和准确诊断的关键，以应对全球范围内日益增加的心血管疾病发病率。这符合当前的需求。

严格规定

严格的法规阻碍了心臟生物标记的开发和实用化。严格的监管核准流程需要广泛的临床检验，通常会导致新生物标记的上市时间较长。这些严格的指南需要进行全面的研究，以确保检测心臟病的准确性、敏感性和特异性。遵守这些法规需要在研究、临床试验和满足特定性能标准方面进行大量投资，这增加了成本和时间限制。

越来越重视即时侦测

即时检测可实现快速、方便的现场诊断，并立即提供结果，而无需将检体发送到中心实验室。在心臟治疗中，这可以快速检测肌钙蛋白等生物标记，从而快速诊断心臟病等心臟疾病。这项转变将透过加快治疗决策（尤其是在紧急情况下）来改善患者照护，也将透过减少週转时间和提高心臟紧急情况管理的整体效率来支持卫生系统。

替代诊断方法的出现

先进影像技术和即时检测设备等新技术可能会提供更快、非侵入性且可能更具成本效益的心臟健康评估方法。此类替代技术可能会挑战传统生物标记测试的主导地位，并影响市场采用和医疗保健提供者的偏好。

COVID-19 的影响：

COVID-19 大流行将医疗资源转移到病毒管理上，影响了心臟生物标记测试。非新冠就诊次数减少导致心臟评估减少，进而影响了生物标记测试的频率。此外，一些新冠肺炎患者出现心臟併发症，增加了对生物标记评估的需求。疫情对医疗保健系统造成的压力已经改变了优先事项，影响了心臟生物标记的利用率，并凸显了在健康危机期间采取适应性诊断策略的必要性。

肌钙蛋白部分预计将在预测期内成为最大的部分

肌钙蛋白片段预计将占据主导地位，因为它们被广泛用作诊断心臟相关疾病的敏感和特异性心臟生物标记。肌钙蛋白，尤其是肌钙蛋白 I 和肌钙蛋白 T，在检测心肌损伤方面表现出良好的敏感性，并且在诊断心臟病发作方面特别有用。由于全世界心血管疾病的盛行率不断增加，且肌钙蛋白检测在日常临床实践中的应用越来越多，预计肌钙蛋白检测将在预测期内成为心臟生物标记检测的最大部分。

医院部门预计在预测期内复合年增长率最高

由于患者在医院环境中获得先进医疗服务和诊断设施的机会增加，医院部门预计将大幅成长。医院是急诊护理的主要中心，心臟生物标记检测在心臟相关疾病的诊断中发挥着至关重要的作用。心血管疾病盛行率的上升以及医院环境中及时、准确诊断的需求正在推动这一领域的预期成长。

比最大的地区

由于其成熟的医疗基础设施、技术进步和高昂的医疗成本，北美预计将主导心臟生物标记市场。该地区强大的研发活动和主要市场参与者的存在帮助其占领了巨大的市场份额。此外，心血管疾病的高盛行率以及人们对先进诊断技术的认识和采用的提高正在推动市场的成长。

复合年增长率最高的地区

由于心血管疾病盛行率的增加、人口老化的加剧以及医疗基础设施的改善，预计亚太地区心臟生物标记市场将显着增长。该地区的心臟健康意识不断增强，推动了对先进诊断工具的需求。此外，政府和医疗机构加强心臟护理的努力也有助于市场扩张。随着医疗技术的进步，随着中国和印度等国家越来越多地采用心臟生物标记物，亚太地区有望见证显着的市场成长。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场公司的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球心臟生物标记市场：依产品类型

  • B 型利尿钠胜肽(BNP)
  • 肌酸激酶 - 肌肉/脑 (CK-MB)
  • 高敏感性 C 反应蛋白 (hs-CRP)
  • 肌红蛋白
  • 肌钙蛋白
  • 其他产品类型

第六章全球心臟生物标记市场：依测试地点

  • 即时检测
  • 临床检查

第七章全球心臟生物标记市场：依应用分类

  • 心肌梗塞
  • 郁血性心臟衰竭
  • 急性冠状动脉症候群
  • 其他用途

第八章全球心臟生物标记市场：依最终用户分类

  • 诊断实验室
  • 医院
  • 製药和生物技术公司
  • 研究机构
  • 其他最终用户

第九章全球心臟生物标记市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第10章 主要进展

  • 协议、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司简介

  • Abbott Laboratories
  • Beckman Coulter
  • Becton, Dickinson and Company（BD）
  • BG Medicine
  • Bio-Rad Laboratories
  • Corgenix
  • Fujirebio
  • Hologic
  • Meso Scale Diagnostics（MSD）
  • Mindray
  • Ortho Clinical Diagnostics
  • Pathkind Labs
  • Qiagen
  • Randox Laboratories
  • R-Biopharm AG
  • Response Biomedical
  • Roche Diagnostics
  • Siemens Healthineers
  • Singulex Inc
  • SRL Diagnostics
  • Thermo Fisher Scientific
  • Trinity Biotech
Product Code: SMRC24900

According to Stratistics MRC, the Global Cardiac Biomarkers Market is accounted for $18.7 billion in 2023 and is expected to reach $54.8 billion by 2030 growing at a CAGR of 16.6% during the forecast period. Cardiac biomarkers are specific molecules or proteins released into the bloodstream due to heart injury, damage or stress. These biomarkers, such as troponins, creatine kinase-MB (CK-MB), and B-type natriuretic peptide (BNP), are used in diagnostics to indicate heart-related conditions. Their detection and levels aid in diagnosing heart attacks, heart failure or other cardiac diseases, guiding treatment decisions and assessing cardiac health.

According to the World Health Organization (WHO), 77 million adults above 18 years have type 2 diabetes, with 25 million prediabetics. This increases cardiovascular disease risk and puts additional pressure on the health system.

Market Dynamics:

Driver:

Rising cardiovascular diseases

With an increasing global burden of heart-related conditions like heart attacks, heart failure and cardiac ischemia, there's a growing demand for reliable diagnostic tools. Cardiac biomarkers serve as vital indicators, aiding in the early detection, diagnosis, and prognosis of cardiovascular ailments. Their ability to accurately assess heart health, predict risks, and guide treatment strategies aligns with the pressing need for efficient, timely, and precise diagnostics in combating the rising incidence of cardiovascular diseases worldwide.

Restraint:

Stringent regulations

Stringent regulations pose a restraint on cardiac biomarker development and implementation. The rigorous approval processes set by regulatory bodies demand extensive clinical validation, often prolonging the time-to-market for new biomarkers. These stringent guidelines necessitate comprehensive studies to ensure accuracy, sensitivity and specificity in detecting cardiac conditions. Compliance with these regulations involves significant investment in research, clinical trials, and meeting specific performance criteria, leading to increased costs and time constraints.

Opportunity:

Increasing focus on point-of-care testing

Point-of-care tests allow for rapid and convenient on-site diagnostics, offering immediate results without the need for sending samples to a central laboratory. In cardiac care, this facilitates quicker detection of biomarkers like troponins, enabling faster diagnosis of heart conditions such as heart attacks. This shift enhances patient care by expediting treatment decisions, especially in emergency settings and supports healthcare systems by reducing turnaround times and improving overall efficiency in managing cardiac emergencies.

Threat:

Emergence of alternative diagnostic methods

New technologies, such as advanced imaging techniques or point-of-care testing devices, might offer rapid, non-invasive and possibly more cost-effective ways to assess cardiac health. These alternatives could challenge the dominance of traditional biomarker testing, impacting market adoption and preferences among healthcare providers.

Covid-19 Impact:

The COVID-19 pandemic influenced cardiac biomarker testing by diverting healthcare resources towards managing the virus. Reduced non-COVID medical visits led to fewer cardiac evaluations, impacting biomarker testing frequency. Additionally, some COVID patients experienced cardiac complications, increasing the demand for biomarker assessments. The pandemic's strain on healthcare systems altered priorities, affecting cardiac biomarker utilisation and emphasising the need for adaptable diagnostic strategies during health crises.

The troponins segment is expected to be the largest during the forecast period

The troponins segment is projected to dominate due to its widespread use as a highly sensitive and specific cardiac biomarker for diagnosing heart-related conditions. Troponins, especially troponin I and troponin T, exhibit superior sensitivity in detecting myocardial injury, notably for diagnosing heart attacks. The growing prevalence of cardiovascular diseases globally and the increasing adoption of troponin testing in routine clinical practice contribute to its anticipated prominence, making it the largest segment in cardiac biomarker testing during the forecast period.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospitals segment is poised for substantial growth due to increased patient access to advanced healthcare services and diagnostic facilities in hospital settings. Hospitals serve as primary centres for acute care, where cardiac biomarker testing plays a pivotal role in diagnosing heart-related conditions. Rising incidences of cardiovascular diseases and the need for timely and accurate diagnostics within hospital environments contribute to the segment's anticipated growth.

Region with largest share:

North America's anticipated dominance in the cardiac biomarkers market is attributed to well-established healthcare infrastructure, technological advancements and high healthcare spending. The region's robust research and development activities, along with the presence of key market players, contribute to its significant market share. Additionally, the high prevalence of cardiovascular diseases, coupled with increasing awareness and adoption of advanced diagnostic techniques, drives market growth.

Region with highest CAGR:

The Asia-Pacific region is poised for substantial growth in the cardiac biomarker market due to the increasing prevalence of cardiovascular diseases, a rising ageing population and improving healthcare infrastructure. The region witnesses a growing awareness of cardiac health, driving demand for advanced diagnostic tools. Additionally, initiatives by governments and healthcare organisations to enhance cardiac care contribute to the market's expansion. The increasing adoption of cardiac biomarkers in countries like China and India, along with advancements in healthcare technologies, positions the Asia-Pacific region for significant market growth.

Key players in the market

Some of the key players in Cardiac Biomarkers Market include Abbott Laboratories, Beckman Coulter, Becton, Dickinson and Company (BD), BG Medicine, Bio-Rad Laboratories, Corgenix , Fujirebio, Hologic, Meso Scale Diagnostics (MSD), Mindray, Ortho Clinical Diagnostics, Pathkind Labs, Qiagen, Randox Laboratories, R-Biopharm AG, Response Biomedical, Roche Diagnostics, Siemens Healthineers, Singulex Inc, SRL Diagnostics, Thermo Fisher Scientific and Trinity Biotech.

Key Developments:

In October 2023, Mindray has announced the introduction and global launch of two new high-sensitivity troponin I (hs-cTnI) and NT-proBNP cardiac biomarkers. The additions enhance Mindray's diverse portfolio of cardiac biomarkers for diagnosing and managing cardiovascular diseases (CVDs), according to a written statement issued by the global medical devices and solutions provider.

In January 2023, Pathkind Labs, Roche Diagnostics partner to release cardiac biomarker. This announcement of NTProBNP comes in light of the growing burden of heart failure among T2D patients in India, inciting the need for urgent action. NTProBNP can directly predict adverse outcomes and cardiovascular mortality and can evaluate the overall status of a patient with type 2 diabetes to facilitate the establishment of correct therapy management and follow-up.

In September 2022, SRL Diagnostics launched "Heart Assure," a specialized test that can predict the risk of a cardiac event in an individual. High-sensitivity troponin I is a simple blood test that can precisely predict a cardiac injury by providing a heart health risk score.

Product Types Covered:

  • B-Type Natriuretic Peptide (BNP)
  • Creatine Kinase-Muscle/Brain (CK-MB)
  • High-Sensitivity C-Reactive Protein (hs-CRP)
  • Myoglobin
  • Troponins
  • Other Product Types

Location of Testings Covered:

  • Point-of-care Testing
  • Laboratory Testing

Applications Covered:

  • Myocardial Infarction
  • Congestive Heart Failure
  • Acute Coronary Syndrome
  • Other Applications

End Users Covered:

  • Diagnostic Laboratories
  • Hospitals
  • Pharmaceutical and Biotechnology Companies
  • Research Institutions
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Cardiac Biomarkers Market, By Product Type

  • 5.1 Introduction
  • 5.2 B-Type Natriuretic Peptide (BNP)
  • 5.3 Creatine Kinase-Muscle/Brain (CK-MB)
  • 5.4 High-Sensitivity C-Reactive Protein (hs-CRP)
  • 5.5 Myoglobin
  • 5.6 Troponins
  • 5.7 Other Product Types

6 Global Cardiac Biomarkers Market, By Location of Testing

  • 6.1 Introduction
  • 6.2 Point-of-care Testing
  • 6.3 Laboratory Testing

7 Global Cardiac Biomarkers Market, By Application

  • 7.1 Introduction
  • 7.2 Myocardial Infarction
  • 7.3 Congestive Heart Failure
  • 7.4 Acute Coronary Syndrome
  • 7.5 Other Applications

8 Global Cardiac Biomarkers Market, By End User

  • 8.1 Introduction
  • 8.2 Diagnostic Laboratories
  • 8.3 Hospitals
  • 8.4 Pharmaceutical and Biotechnology Companies
  • 8.5 Research Institutions
  • 8.6 Other End Users

9 Global Cardiac Biomarkers Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Abbott Laboratories
  • 11.2 Beckman Coulter
  • 11.3 Becton, Dickinson and Company (BD)
  • 11.4 BG Medicine
  • 11.5 Bio-Rad Laboratories
  • 11.6 Corgenix
  • 11.7 Fujirebio
  • 11.8 Hologic
  • 11.9 Meso Scale Diagnostics (MSD)
  • 11.10 Mindray
  • 11.11 Ortho Clinical Diagnostics
  • 11.12 Pathkind Labs
  • 11.13 Qiagen
  • 11.14 Randox Laboratories
  • 11.15 R-Biopharm AG
  • 11.16 Response Biomedical
  • 11.17 Roche Diagnostics
  • 11.18 Siemens Healthineers
  • 11.19 Singulex Inc
  • 11.20 SRL Diagnostics
  • 11.21 Thermo Fisher Scientific
  • 11.22 Trinity Biotech

List of Tables

  • Table 1 Global Cardiac Biomarkers Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Cardiac Biomarkers Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 3 Global Cardiac Biomarkers Market Outlook, By B-Type Natriuretic Peptide (BNP) (2021-2030) ($MN)
  • Table 4 Global Cardiac Biomarkers Market Outlook, By Creatine Kinase-Muscle/Brain (CK-MB) (2021-2030) ($MN)
  • Table 5 Global Cardiac Biomarkers Market Outlook, By High-Sensitivity C-Reactive Protein (hs-CRP) (2021-2030) ($MN)
  • Table 6 Global Cardiac Biomarkers Market Outlook, By Myoglobin (2021-2030) ($MN)
  • Table 7 Global Cardiac Biomarkers Market Outlook, By Troponins (2021-2030) ($MN)
  • Table 8 Global Cardiac Biomarkers Market Outlook, By Other Product Types (2021-2030) ($MN)
  • Table 9 Global Cardiac Biomarkers Market Outlook, By Location of Testing (2021-2030) ($MN)
  • Table 10 Global Cardiac Biomarkers Market Outlook, By Point-of-care Testing (2021-2030) ($MN)
  • Table 11 Global Cardiac Biomarkers Market Outlook, By Laboratory Testing (2021-2030) ($MN)
  • Table 12 Global Cardiac Biomarkers Market Outlook, By Application (2021-2030) ($MN)
  • Table 13 Global Cardiac Biomarkers Market Outlook, By Myocardial Infarction (2021-2030) ($MN)
  • Table 14 Global Cardiac Biomarkers Market Outlook, By Congestive Heart Failure (2021-2030) ($MN)
  • Table 15 Global Cardiac Biomarkers Market Outlook, By Acute Coronary Syndrome (2021-2030) ($MN)
  • Table 16 Global Cardiac Biomarkers Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 17 Global Cardiac Biomarkers Market Outlook, By End User (2021-2030) ($MN)
  • Table 18 Global Cardiac Biomarkers Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 19 Global Cardiac Biomarkers Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 20 Global Cardiac Biomarkers Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 21 Global Cardiac Biomarkers Market Outlook, By Research Institutions (2021-2030) ($MN)
  • Table 22 Global Cardiac Biomarkers Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 23 North America Cardiac Biomarkers Market Outlook, By Country (2021-2030) ($MN)
  • Table 24 North America Cardiac Biomarkers Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 25 North America Cardiac Biomarkers Market Outlook, By B-Type Natriuretic Peptide (BNP) (2021-2030) ($MN)
  • Table 26 North America Cardiac Biomarkers Market Outlook, By Creatine Kinase-Muscle/Brain (CK-MB) (2021-2030) ($MN)
  • Table 27 North America Cardiac Biomarkers Market Outlook, By High-Sensitivity C-Reactive Protein (hs-CRP) (2021-2030) ($MN)
  • Table 28 North America Cardiac Biomarkers Market Outlook, By Myoglobin (2021-2030) ($MN)
  • Table 29 North America Cardiac Biomarkers Market Outlook, By Troponins (2021-2030) ($MN)
  • Table 30 North America Cardiac Biomarkers Market Outlook, By Other Product Types (2021-2030) ($MN)
  • Table 31 North America Cardiac Biomarkers Market Outlook, By Location of Testing (2021-2030) ($MN)
  • Table 32 North America Cardiac Biomarkers Market Outlook, By Point-of-care Testing (2021-2030) ($MN)
  • Table 33 North America Cardiac Biomarkers Market Outlook, By Laboratory Testing (2021-2030) ($MN)
  • Table 34 North America Cardiac Biomarkers Market Outlook, By Application (2021-2030) ($MN)
  • Table 35 North America Cardiac Biomarkers Market Outlook, By Myocardial Infarction (2021-2030) ($MN)
  • Table 36 North America Cardiac Biomarkers Market Outlook, By Congestive Heart Failure (2021-2030) ($MN)
  • Table 37 North America Cardiac Biomarkers Market Outlook, By Acute Coronary Syndrome (2021-2030) ($MN)
  • Table 38 North America Cardiac Biomarkers Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 39 North America Cardiac Biomarkers Market Outlook, By End User (2021-2030) ($MN)
  • Table 40 North America Cardiac Biomarkers Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 41 North America Cardiac Biomarkers Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 42 North America Cardiac Biomarkers Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 43 North America Cardiac Biomarkers Market Outlook, By Research Institutions (2021-2030) ($MN)
  • Table 44 North America Cardiac Biomarkers Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 45 Europe Cardiac Biomarkers Market Outlook, By Country (2021-2030) ($MN)
  • Table 46 Europe Cardiac Biomarkers Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 47 Europe Cardiac Biomarkers Market Outlook, By B-Type Natriuretic Peptide (BNP) (2021-2030) ($MN)
  • Table 48 Europe Cardiac Biomarkers Market Outlook, By Creatine Kinase-Muscle/Brain (CK-MB) (2021-2030) ($MN)
  • Table 49 Europe Cardiac Biomarkers Market Outlook, By High-Sensitivity C-Reactive Protein (hs-CRP) (2021-2030) ($MN)
  • Table 50 Europe Cardiac Biomarkers Market Outlook, By Myoglobin (2021-2030) ($MN)
  • Table 51 Europe Cardiac Biomarkers Market Outlook, By Troponins (2021-2030) ($MN)
  • Table 52 Europe Cardiac Biomarkers Market Outlook, By Other Product Types (2021-2030) ($MN)
  • Table 53 Europe Cardiac Biomarkers Market Outlook, By Location of Testing (2021-2030) ($MN)
  • Table 54 Europe Cardiac Biomarkers Market Outlook, By Point-of-care Testing (2021-2030) ($MN)
  • Table 55 Europe Cardiac Biomarkers Market Outlook, By Laboratory Testing (2021-2030) ($MN)
  • Table 56 Europe Cardiac Biomarkers Market Outlook, By Application (2021-2030) ($MN)
  • Table 57 Europe Cardiac Biomarkers Market Outlook, By Myocardial Infarction (2021-2030) ($MN)
  • Table 58 Europe Cardiac Biomarkers Market Outlook, By Congestive Heart Failure (2021-2030) ($MN)
  • Table 59 Europe Cardiac Biomarkers Market Outlook, By Acute Coronary Syndrome (2021-2030) ($MN)
  • Table 60 Europe Cardiac Biomarkers Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 61 Europe Cardiac Biomarkers Market Outlook, By End User (2021-2030) ($MN)
  • Table 62 Europe Cardiac Biomarkers Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 63 Europe Cardiac Biomarkers Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 64 Europe Cardiac Biomarkers Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 65 Europe Cardiac Biomarkers Market Outlook, By Research Institutions (2021-2030) ($MN)
  • Table 66 Europe Cardiac Biomarkers Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 67 Asia Pacific Cardiac Biomarkers Market Outlook, By Country (2021-2030) ($MN)
  • Table 68 Asia Pacific Cardiac Biomarkers Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 69 Asia Pacific Cardiac Biomarkers Market Outlook, By B-Type Natriuretic Peptide (BNP) (2021-2030) ($MN)
  • Table 70 Asia Pacific Cardiac Biomarkers Market Outlook, By Creatine Kinase-Muscle/Brain (CK-MB) (2021-2030) ($MN)
  • Table 71 Asia Pacific Cardiac Biomarkers Market Outlook, By High-Sensitivity C-Reactive Protein (hs-CRP) (2021-2030) ($MN)
  • Table 72 Asia Pacific Cardiac Biomarkers Market Outlook, By Myoglobin (2021-2030) ($MN)
  • Table 73 Asia Pacific Cardiac Biomarkers Market Outlook, By Troponins (2021-2030) ($MN)
  • Table 74 Asia Pacific Cardiac Biomarkers Market Outlook, By Other Product Types (2021-2030) ($MN)
  • Table 75 Asia Pacific Cardiac Biomarkers Market Outlook, By Location of Testing (2021-2030) ($MN)
  • Table 76 Asia Pacific Cardiac Biomarkers Market Outlook, By Point-of-care Testing (2021-2030) ($MN)
  • Table 77 Asia Pacific Cardiac Biomarkers Market Outlook, By Laboratory Testing (2021-2030) ($MN)
  • Table 78 Asia Pacific Cardiac Biomarkers Market Outlook, By Application (2021-2030) ($MN)
  • Table 79 Asia Pacific Cardiac Biomarkers Market Outlook, By Myocardial Infarction (2021-2030) ($MN)
  • Table 80 Asia Pacific Cardiac Biomarkers Market Outlook, By Congestive Heart Failure (2021-2030) ($MN)
  • Table 81 Asia Pacific Cardiac Biomarkers Market Outlook, By Acute Coronary Syndrome (2021-2030) ($MN)
  • Table 82 Asia Pacific Cardiac Biomarkers Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 83 Asia Pacific Cardiac Biomarkers Market Outlook, By End User (2021-2030) ($MN)
  • Table 84 Asia Pacific Cardiac Biomarkers Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 85 Asia Pacific Cardiac Biomarkers Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 86 Asia Pacific Cardiac Biomarkers Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 87 Asia Pacific Cardiac Biomarkers Market Outlook, By Research Institutions (2021-2030) ($MN)
  • Table 88 Asia Pacific Cardiac Biomarkers Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 89 South America Cardiac Biomarkers Market Outlook, By Country (2021-2030) ($MN)
  • Table 90 South America Cardiac Biomarkers Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 91 South America Cardiac Biomarkers Market Outlook, By B-Type Natriuretic Peptide (BNP) (2021-2030) ($MN)
  • Table 92 South America Cardiac Biomarkers Market Outlook, By Creatine Kinase-Muscle/Brain (CK-MB) (2021-2030) ($MN)
  • Table 93 South America Cardiac Biomarkers Market Outlook, By High-Sensitivity C-Reactive Protein (hs-CRP) (2021-2030) ($MN)
  • Table 94 South America Cardiac Biomarkers Market Outlook, By Myoglobin (2021-2030) ($MN)
  • Table 95 South America Cardiac Biomarkers Market Outlook, By Troponins (2021-2030) ($MN)
  • Table 96 South America Cardiac Biomarkers Market Outlook, By Other Product Types (2021-2030) ($MN)
  • Table 97 South America Cardiac Biomarkers Market Outlook, By Location of Testing (2021-2030) ($MN)
  • Table 98 South America Cardiac Biomarkers Market Outlook, By Point-of-care Testing (2021-2030) ($MN)
  • Table 99 South America Cardiac Biomarkers Market Outlook, By Laboratory Testing (2021-2030) ($MN)
  • Table 100 South America Cardiac Biomarkers Market Outlook, By Application (2021-2030) ($MN)
  • Table 101 South America Cardiac Biomarkers Market Outlook, By Myocardial Infarction (2021-2030) ($MN)
  • Table 102 South America Cardiac Biomarkers Market Outlook, By Congestive Heart Failure (2021-2030) ($MN)
  • Table 103 South America Cardiac Biomarkers Market Outlook, By Acute Coronary Syndrome (2021-2030) ($MN)
  • Table 104 South America Cardiac Biomarkers Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 105 South America Cardiac Biomarkers Market Outlook, By End User (2021-2030) ($MN)
  • Table 106 South America Cardiac Biomarkers Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 107 South America Cardiac Biomarkers Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 108 South America Cardiac Biomarkers Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 109 South America Cardiac Biomarkers Market Outlook, By Research Institutions (2021-2030) ($MN)
  • Table 110 South America Cardiac Biomarkers Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 111 Middle East & Africa Cardiac Biomarkers Market Outlook, By Country (2021-2030) ($MN)
  • Table 112 Middle East & Africa Cardiac Biomarkers Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 113 Middle East & Africa Cardiac Biomarkers Market Outlook, By B-Type Natriuretic Peptide (BNP) (2021-2030) ($MN)
  • Table 114 Middle East & Africa Cardiac Biomarkers Market Outlook, By Creatine Kinase-Muscle/Brain (CK-MB) (2021-2030) ($MN)
  • Table 115 Middle East & Africa Cardiac Biomarkers Market Outlook, By High-Sensitivity C-Reactive Protein (hs-CRP) (2021-2030) ($MN)
  • Table 116 Middle East & Africa Cardiac Biomarkers Market Outlook, By Myoglobin (2021-2030) ($MN)
  • Table 117 Middle East & Africa Cardiac Biomarkers Market Outlook, By Troponins (2021-2030) ($MN)
  • Table 118 Middle East & Africa Cardiac Biomarkers Market Outlook, By Other Product Types (2021-2030) ($MN)
  • Table 119 Middle East & Africa Cardiac Biomarkers Market Outlook, By Location of Testing (2021-2030) ($MN)
  • Table 120 Middle East & Africa Cardiac Biomarkers Market Outlook, By Point-of-care Testing (2021-2030) ($MN)
  • Table 121 Middle East & Africa Cardiac Biomarkers Market Outlook, By Laboratory Testing (2021-2030) ($MN)
  • Table 122 Middle East & Africa Cardiac Biomarkers Market Outlook, By Application (2021-2030) ($MN)
  • Table 123 Middle East & Africa Cardiac Biomarkers Market Outlook, By Myocardial Infarction (2021-2030) ($MN)
  • Table 124 Middle East & Africa Cardiac Biomarkers Market Outlook, By Congestive Heart Failure (2021-2030) ($MN)
  • Table 125 Middle East & Africa Cardiac Biomarkers Market Outlook, By Acute Coronary Syndrome (2021-2030) ($MN)
  • Table 126 Middle East & Africa Cardiac Biomarkers Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 127 Middle East & Africa Cardiac Biomarkers Market Outlook, By End User (2021-2030) ($MN)
  • Table 128 Middle East & Africa Cardiac Biomarkers Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 129 Middle East & Africa Cardiac Biomarkers Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 130 Middle East & Africa Cardiac Biomarkers Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 131 Middle East & Africa Cardiac Biomarkers Market Outlook, By Research Institutions (2021-2030) ($MN)
  • Table 132 Middle East & Africa Cardiac Biomarkers Market Outlook, By Other End Users (2021-2030) ($MN)